Parabilis Medicines, Inc.

NASDAQ: PBLS · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexReports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 44

v0.1 · 5/100 weight · pillars only

↑ workforce scale, market scale · ↓ listing tenure, market scale

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

145

Market cap

$96.9M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Parabilis Medicines, Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

biote Corp.63C Neuronetics, Inc.59C Ascend Wellness Holdings, Inc.53D Cumberland Pharmaceuticals Inc.70B

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Alnylam Pharmaceuticals, Inc.$3.7B79B+

Key facts

CEOMathai Mammen

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeNASDAQ: PBLS

Employees145

IPO date2026-06-10

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.